Latest News
Starpharma signs new DEP® agreement with MSD
Aug 10th, 2022
Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.
Read MoreQuarterly Activities Report & Appendix 4C
Jul 29th, 2022
Starpharma today released its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2022.
Read MoreVIRALEZE Protects Against Omicron in Viral Challenge Model (ASX Announcement)
Jul 20th, 2022
Starpharma today announced new results demonstrating the high level of protection afforded by VIRALEZE™ antiviral nasal spray against the highly infectious SARS-CoV-2 Omicron variant in vivo in a well-established humanised mouse challenge model of coronavirus infection. Challenge models are often used in viral diseases to assess the ability of a product to treat or prevent an infection.
Read More
VIRALEZE™ relaunched by LloydsPharmacy in the UK (ASX Announcement)
Jun 30th, 2022
Starpharma today announced that VIRALEZE™ nasal spray has been relaunched by LloydsPharmacy in the UK.
Read More